ViiV/GSK
Royalty Monetization$61 Million
May 2008
MarketerViiV/GSK
LEXIVA® (Telzir® in the European Union) is a protease inhibitor for the treatment of HIV/AIDS infection. The product has a strong long term safety profile and is currently approved for sale in approximately 45 countries. Lexiva was developed and commercialized under a license agreement between GlaxoSmithKline and Vertex Pharmaceuticals.